CTEV
Claritev Corporation
CTEV offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CTEV overall, supported by lower modeled downside and stronger valuation.
CTEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
CTEV's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CTEV PE Valuation
CTEV has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CTEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect CTEV's revenue to grow, with its earnings and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CTEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$16.42 | +$4.87 |
| Q2 2026 | -$17.01 | +$24.30 |
| Q1 2026 | -$17.33 | +$55.77 |
| Q4 2025 | -$17.30 | +$84.62 |
| Q3 2025 | -$21.29 | +$73.36 |
| Q2 2025 | -$41.31 | +$30.69 |
| Q1 2025 | -$73.10 | -$34.30 |
| Q4 2024 | -$101.92 | -$96.32 |
CTEV is still losing money, but far less than before: $16.42 per share over the past year, against $101.92 at its worst in late 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CTEV on earnings quality, reporting a profit while its opponent remains loss making.
CTEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.3M | +9.1% |
| Q2 2026 | $257.5M | +6.6% |
| Q1 2026 | $244.7M | +5.8% |
| Q4 2025 | $246.6M | +6.2% |
| Q3 2025 | $246M | +6.7% |
| Q2 2025 | $241.6M | +3.5% |
| Q1 2025 | $231.3M | -1.4% |
| Q4 2024 | $232.1M | -4.9% |
CTEV's revenue has grown year over year for six quarters in a row: $268M last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +3.6 points |
| Q2 2026 | 9.1% | +2.2 points |
| Q1 2026 | 2.7% | -1.5 points |
| Q4 2025 | -3.1% | +15 points |
| Q3 2025 | 4.1% | +151 points |
| Q2 2025 | 6.9% | +231 points |
| Q1 2025 | 4.2% | +212 points |
| Q4 2024 | -18% | -35 points |
CTEV has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CTEV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CTEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.2M | -$9.9M |
| Q2 2026 | $54.6M | +49% |
| Q1 2026 | -$92.5M | -$23.6M |
| Q4 2025 | $36.4M | +$100.2M |
| Q3 2025 | -$16.3M | -140% |
| Q2 2025 | $36.6M | +$43.6M |
| Q1 2025 | -$68.9M | -459% |
| Q4 2024 | -$63.8M | -$60.2M |
CTEV's free cash flow was −$28M over the past year, against −$113M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CTEV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +10.3K shares |
| 1 year | +3% | +495K shares |
| 3 years | +5% | +814K shares |
| 5 years | +4% | +653K shares |
| Available history | +562% | +14.4M shares |
CTEV has 17M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CTEV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CTEV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.4x | High |
| Q2 2026 | 9.6x | High |
| Q1 2026 | 9.7x | High |
| Q4 2025 | 9.6x | High |
| Q3 2025 | 10.3x | High |
| Q2 2025 | 52.3x | High |
| Q1 2024 | 85.5x | High |
| Q4 2023 | 7.7x | High |
CTEV's net debt is about 9.4 years of its operating earnings (EBITDA), down from 10 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over CTEV on leverage, with a lower net debt burden relative to earnings.
CTEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.9 | Neutral |
| Stochastic | 21.6 | Neutral |
CTEV's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CTEV PE vs Healthcare Sector
| Metric | CTEV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTEV has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CTEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.9 | 13% above |
| 20 week MA | $29.1 | 7.6% below |
| 50 week MA | $26.9 | 0.1% below |
| 100 week MA | $32.3 | 17% below |
| 200 week MA | $36.3 | 26% below |
CTEV has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CTEV on trend strength, trading above more of its moving averages.
CTEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.8 | $357.2 | -8.1% |
| 2021 | $357.2 | $176.8 | -51% |
| 2022 | $176.8 | $47.6 | -73% |
| 2023 | $47.6 | $57.6 | +21% |
| 2024 | $57.6 | $17.5 | -70% |
| 2025 | $17.5 | $42.0 | +140% |
| 2026 YTD | $42.0 | $26.9 | -36% |
CTEV's yearly returns have swung widely, from +140% in 2025 to −73% in 2022. It's down 36% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CTEV on returns for 2026, with the stronger performance.